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§Department of Chemistry and Biochemistry, University of California at Santa Barbara, Santa Barbara, CaliforniaABSTRACT The abnormal self-assembly of a number of proteins or peptides is a hallmark of >20 amyloidogenic diseases.
Recent studies suggest that the pathology of amyloidogenesis can be attributed primarily to cytotoxic, soluble, intermediate olig-
omeric species rather than to mature amyloid fibrils. Despite the lack of available structural information regarding these transient
species, many therapeutic efforts have focused on inhibiting the formation of these aggregates. One of the most successful
approaches has been to use small molecules, many of which have been found to inhibit toxic species with high efficacy. A signif-
icant issue that remains to be resolved is the mechanism underlying the inhibitory effects of these molecules. In this article, we
present extensive replica-exchange molecular dynamics simulations to study the early aggregation of the human islet amyloid
polypeptide segment 22–27 in the presence and absence of the small-molecule inhibitor resveratrol. The simulations indicate
that aggregation of these peptides was hindered by resveratrol via a mechanism of blocking the lateral growth of a single-layered
b-sheet oligomer (rather than preventing growth by elongation along the fibril axis). Intersheet side-chain stacking, especially
stacking of the aromatic rings, was blocked by the presence of resveratrol molecules, and the overall aggregation level was
reduced.INTRODUCTIONAmyloidogenic diseases belong to a range of neurodegener-
ative or metabolic disorders characterized by abnormal self-
assembly of locally expressed proteins or peptides (1)
whose end-products of self-assembly exhibit a similar
pleated b-sheet fibrillar morphology (2). It is interesting to
note that recent studies indicate that the main cytotoxicity
of these amyloidogenic peptides is not linked to mature
fibrils but rather to soluble, intermediate oligomeric species
(2–5). To interrupt the oligomer formation by chemical
substances could be one promising way to alleviate the
toxicity.
The most common antiamyloid small-molecule inhibitors
belong to the family of polyphenol compounds and contain
two common functional moieties: aromatic rings and polar
groups on the rings (2). Novel inhibitor molecules were
designed based on the unique scaffold obtained from these
compounds (2,6). The resulting small-molecule inhibitors
can be very active even in the presence of membranes
(7,8). Different molecules show distinct inhibition behav-
iors: some inhibitors block the formation of oligomers but
promote fibril formation, some block the formation of fibrils
but not oligomers, and others block both (9–11). However,
the underlying inhibition mechanism is not yet completely
clear.
In this study, we attempted to characterize the interactions
between a small molecule, resveratrol, and human islet
amyloid polypeptide segment 22–27 (hIAPP22–27), anSubmitted December 6, 2010, and accepted for publication February 3,
2011.
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peptide implicated in Type II diabetes. Resveratrol is
a well-known constituent of red wine and a small poly-
phenol found to be capable of inhibiting hIAPP fibril forma-
tion efficiently (7,8,12). The hIAPP22–27 segment alone was
found to be amyloidogenic and capable of forming typical
amyloid fibrils (13). The sequence NFGAIL in humans
differs by three amino acids from the rodent IAPP
(NLGPVL), which together with three other mutations in
full-length IAPPs defines the divergent aggregation ability
of rodent species (13,14). The hIAPP22–27 sequence is
hydrophobic, and the aromatic residue F23 is believed to
play a key role in aggregation through the formation of
aromatic interactions. Given the aromatic nature of resvera-
trol, similar aromatic interactions could be important in
inhibition processes (2,15). Therefore, hIAPP22–27 is a suit-
able model peptide to study amyloid aggregation. Our goal
was to investigate the effect of the inhibitor on the early
steps of aggregation rather than the interaction of the inhib-
itor with a preformed fibril. We used extensive replica-
exchange molecular-dynamics (REMD) simulations, with
seven copies of the short peptide model. We considered
a preformed b-sheet tetramer as the aggregation nucleus
together with three free peptides (15). The self-assembly
of the short peptide was studied with and without resveratrol
(7,8,12). The simulation results revealed that lateral associ-
ation occurs at a very early phase of aggregation and that the
impact of resveratrol on early oligomers lies in its blockage
of the lateral association. Competing with free peptides,
resveratrol molecules bind to the hydrophobic side chains,
which play key roles in mediating b-sheet stacking.doi: 10.1016/j.bpj.2011.02.010
FIGURE 1 (A) Molecular geometry of trans-resveratrol. All carbon
atoms are distinguished by sequential numbers (black), and oxygen atoms
on three hydroxyl groups are labeled with red numbers. (B) Cartoon repre-
sentation of seven strands of hIAPP22–27. A preformed parallel-b-sheet
tetramer (red online) at center is surrounded by three APMs (blue online)
placed at least 10 A˚ away from the tetramer.
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Parameterization and validation
of the resveratrol model
The structure of the small molecule resveratrol is shown in Fig. 1 A. The
initial topology for trans-resveratrol was generated in Spartan and
energy-minimized (16). After geometry optimization at the HF/6-31G*
level using Gaussian09 (17), atomic partial charges were derived using
the R.E.D. III package (18). Other bonded and nonbonded parameters of
resveratrol were taken from the optimized potentials for liquid simulations
all-atom (OPLS-AA) force field (19). The details of validation of the
parameters can be found in the Supporting Material.Replica-exchange molecular-dynamics
simulations
We chose a short segment of hIAPP22–27, known to be amyloidogenic, as
a peptide model to study amyloid aggregation (15). Recent studies have
shown that other segments from hIAPP can also form an amyloid structure
(20–22). The initial conformation for our simulations consists of a parallel
b-sheet (23) consisting of four strands centered in a dodecahedron box with
a size of 40 A˚ and surrounded by three monomers, each rotated 120 from
the others and placed at least 10 A˚ from the b-sheet (Fig. 1 B). We will refer
to the four strands of peptide segment in the preformed b-sheet as pre-
formed b-peptides (PBPs). The three peptide monomers that were initially
positioned away from the PBPs are referred to as added peptide monomers(APMs). To cover more sampling space, the APMs were rotated around the
PBPs 30 each time to generate a total of four different initial configurations
(after four rotations, APM peptides adopt the same conformational config-
uration as one with no rotation, so we do not consider further rotations).
The N- and C-termini of hIAPP22–27 were capped by acetyl (ACE) and
N-methyl (NME) groups. We expect that the PBP tetramer can act as an
aggregation seed to accelerate the overall aggregation process. However,
the PBP was not subject to any type of restraint during simulations, because
the tetrameric b-sheet for such a short peptide is neither stable nor compe-
tent to work as an aggregation nucleus. In fact, the PBP was found to be
partially stabilized and undergo large structural fluctuation and reorganiza-
tion, as we expected. A temperature-swapping REMD simulation scheme
was performed using the Gromacs simulation package with the OPLS-
AA force field for the peptides (20,26), with 32 replicas. If not explicitly
marked, the data used were obtained from the lowest temperature, 315 K.
All the error bars were obtained through block averages: the last 300 ns
of data were divided into three 100-ns segments. The details of the
REMD method can be found in the Supporting Material.Binding energy calculation
The binding energy of resveratrol on hIAPP22–27 peptides can be estimated
using the molecular mechanics generalized Born/surface area (MM-GBSA)
method (24) in the equation
DEbind ¼ Ecomplex  Epeptide  Eresveratrol;
where Ecomplex, Epeptide, and Eresveratrol are the total potential energies of the
resveratrol-peptide complex, peptide alone, and resveratrol alone, respec-
tively. Each of the three energy values in the equation can be decomposed
into three terms: the intraprotein potential energy (the MM term), calcu-
lated by the Gromacs package; the polar part of the solvation energy (the
GB term), estimated by using the generalized Born model; and the nonpolar
part of the solvation energy (the SA term). The last two solvation parts were
calculated in the sander module of the AMBER 9 package (25,26). The
source code of the Amber leap program was modified in-house to import
nonbonded parameters from the OPLS-AA force field.RESULTS
Evolution of b secondary structure in the
hIAPP22–27 peptide in the absence of resveratrol
The assembly progress of the hIAPP22–27 peptide was moni-
tored by examining the b secondary structure evolution in
the presence and absence of the inhibitor (Fig. 2). All the
data are obtained from the lowest temperature ensemble.
The b secondary structure formation was quantified by
b-content, the ratio of the number of residues in b secondary
structure to the total number of residues (42 in this study).
As an initial condition for our study, a parallel b-sheet
composed of four peptide strands (PBPs) was formed,
with three APMs, as described in the Methods section.
During the first 50 ns of the simulation, the b-content in
PBPs sharply decreases and loses nearly half the b-structure
(black solid line). Afterward, the b-content of the PBP
fluctuates around 0.25 until the end of the 500-ns simula-
tion. The b-content of the APM grows constantly during
the first 400 ns. After that, the b-content arrives at the
plateau of 0.25 (gray solid line). It is interesting to find
that regardless of the initial configuration of the peptides,Biophysical Journal 100(6) 1550–1558
FIGURE 2 Time evolution of the b-content of PBPs and APMs in the
absence and presence of resveratrol. b-content is the ratio of the number
of residues in b secondary structure to the total residue number for each
species, 24 for PBP and 18 for APM. Each data point on the curves is an
average over 10,000 time frames (10 ns). The secondary structures of
peptides were assessed by the DSSP algorithm (45). All data are from the
ensemble of T ¼ 315 K.
1552 Jiang et al.either in preformed b-sheet or in random monomers, the
b-content is approaching 0.25 at the end of the 500-ns
simulation.Aggregation of the hIAPP22–27 peptide
in the absence of resveratrol
We classified the hIAPP22–27 peptide oligomers formed in
our simulations based on two separate criteria. The first is
that at least two interstrand backbone hydrogen bonds are
formed. Under this criterion, peptide aggregates can be
grouped into different b-sheet oligomers (BSOs). The
second criterion is based only on interresidue distances: at
least four pairs of residues must form interstrand atomic
contacts. An atomic contact between two residues is consid-
ered to be formed when the minimum interresidue distance
between any pair of heavy atoms is <5 A˚. Based on this
criterion, peptide aggregates can be divided into different
collapsed oligomers (CLO). In our classification, the criteriaBiophysical Journal 100(6) 1550–1558of two hydrogen bonds in BSOs and four atomic contacts in
CLOs are somewhat arbitrarily chosen. We found that
changing these thresholds changed the population of
different aggregates; however, the results regarding the
behavior in the absence or presence of resveratrol were
tolerant to the changes.
We observed in our simulations that the seven peptide
strands form many types of oligomers. The system configu-
ration can be described by the number of oligomers and the
related oligomer size, which is the number of strands in one
oligomer. We used the following conventions, based on size,
to label the configurations. For example, 7 or 7* means the
seven peptides form a heptameric BSO or CLO. A label
such as 6.1 indicates the presence of two BSO oligomers
in which one is a hexamer and one is a monomer. The 1 is
omitted for simplicity, so that 6.1 is simplified to 6. A
system label of 4 is in fact 4.1.1.1, which means four
different oligomers of which one is a tetramer and three
are monomers. The reason we used two criteria is that
they can provide complementary information. For example,
for a configuration with two BSOs, the information about
whether the two BSOs are close to each other in space is
lost. If one can check that the two BSOs belong to one
CLO, then it is clear that the two BSOs are close in space,
whereas if the two BSOs belong to two CLOs, then the
two BSOs are far away from each other. The distributions
of aggregate patterns are shown in Fig. 3.
The distribution of BSOs (Fig. 3 A) indicates that the
peptides have an equal possibility of forming single-sheet
(or single-BSO, including sizes 7, 6, 5, 4, 3, and 2) aggre-
gates or double-sheet aggregates (sizes 5.2, 4.3, 4.2, 3.3,
3.2, and 2.2). The evidence that 70% of aggregates are hep-
tameric CLOs (size 7* (Fig. 3 B)) implies that 70% of aggre-
gates in all BSO configurations have their component
strands packed into condensed aggregates. This result shows
that single-layer b-sheets, i.e., BSOs of 7 and 6, have very
small populations, which indicates that elongation along
a single b-sheet may not be the primary mode of nucleation
formation. The formation of double-layered b-sheets is an
important event that is also unexpected in our simulations.FIGURE 3 (A) Species distribution of b-sheet
aggregates. (B) Species distribution of collapsed
aggregates. See text for definition of b-sheet aggre-
gates and collapsed aggregates. Aggregates with
very small populations are excluded from the
figures. All data are from the ensemble of T ¼
315 K.
FIGURE 4 Representative structures of aggregates with double b-sheets.
Percentages in parentheses show the size of the first-ranked cluster in the
overall aggregates with certain size. The stacking side chains are indicated
by red balls and sticks. Peptide backbones are shown as ribbons, yellow for
oligomers and green for monomers. Resveratrol molecules are shown in
black, line representation. All six aggregates in the absence of resveratrol
(A–F) show a multilayer arrangement. (G–I) Three aggregates in the pres-
ence of resveratrol. Except in the case of 4.2 (H), there are no side-chain
contacts between the two b sheets.
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gates, an root-mean-squared deviation (RMSD) clustering
(27) was performed. For different aggregate species, the
structures of the cluster center of the top-ranked clusters
were taken as representative structures (Fig. 4). The
percentage of each top-ranked cluster in each species is
also shown in parentheses. The RMSD calculation was
based on heptamers, and unstructured monomers can cause
large RMSD fluctuations that result in classification without
an especially dominant top-ranked cluster, such as for size
2.2 (only 8.0%).
In these double-sheet aggregates, we found that one layer
of b-sheets usually evolves from the PBPs, and we refer to
this layer as the primary b-sheet; the other layer is formed
by APM self-assembly and referred to as the secondary
b-sheet. The secondary b-sheet (upper b-sheet layer in
Fig. 4, A–F) tends to lie parallel to the primary b-sheet
(the lower layer), involving extensive side-chain stacking
interactions (explicitly shown as red balls and sticks), in
a face-to-face configuration. Such an arrangement prevents
exposure of hydrophobic residues to solvents and thereby
stabilizes stacking b-sheets. Even in the small aggregates,
such as double dimers (Fig. 4 F), the face-to-face intersheetinteraction is already formed, suggesting a natural pathway
in which lateral extension occurs simultaneously with elon-
gation at the very early stage of amyloid aggregation. In
fact, the structure of single-layer aggregates of larger sizes,
such as heptamers (size 7), is not a normal planar b-sheet.
Instead, it takes the form of a b-barrel by wrapping inward
several side chains (see Fig. S1 in the Supporting Material).
The planar b-sheet structures of short peptides resolved by
microcrystal also demonstrate intimately steric zippering
of side chains (28,29). Thus, side-chain interactions, as
well as backbone hydrogen bonds are the main driving
forces during the early aggregation process.Distinct evolution of b-content in the presence
of resveratrol
When resveratrol molecules are added into the system, the
peptides show distinct self-assembly behaviors. After 100
ns, the b-content of the PBP is stabilized around 0.3
(Fig. 2, black dotted line), which is higher than the value
of its counterpart in the absence of resveratrol (~0.25).
The evolution of b-structures in APMs is much slower,
taking nearly 400 ns to reach a steady level (Fig. 2, gray
dotted line) of ~0.20, which is smaller than the value of
its counterpart in the absence of resveratrol (~0.25). It seems
that resveratrol acts to maintain the preformed b-structure
but prevent the monomers from forming new b-structure
(with the PBPs). Ideally, the b-content of PBPs and APMs
should be identical. Our simulations indicate that such
an equilibration process is far beyond the timescale of
500 ns. Of more importance, we found that even though
the b-content does not show significant differences between
the two ensembles (with and without resveratrol), it does not
mean that the two ensembles are the same. The different
inhibitory effects of resveratrol on PBPs and APMs are
further analyzed from a thermodynamic perspective.Thermodynamic evidence of the distinct
effects of resveratrol
We compared the population of monomeric peptides and
b-content as a function of temperature for the system with
and without resveratrol (Fig. 5, A and B). Data were
analyzed based on the last 300 ns of simulations at all
temperatures. The amount of monomeric peptides remain-
ing in solution is a normal measure in experiments to detect
the extent of amyloid aggregation (30). In the presence of
resveratrol, the abundance of monomers unambiguously
exceeds that in the absence of resveratrol at all tempera-
tures, indicating the inhibitory effect of the compound on
peptide aggregation (Fig. 5 A). The b-content results illus-
trate the same effect (Fig. 5 B). Although at low tempera-
tures the amount of b-structure is equal in the two
systems, at higher temperatures, the b-content is evidently
lower in the presence of resveratrol than in its absence.Biophysical Journal 100(6) 1550–1558
FIGURE 5 Temperature-dependent features of peptide aggregation.
(A) Proportion of peptide monomers, the ratio of the number of monomers
to the total number of peptide strands. (B) b-content. (C) b-content contri-
butions from PBPs and APMs. (D) Histogram statistics of survival ratios of
the preformed hydrogen bonds. Calculations of A–C are based on data from
the last 300 ns of simulations. Error bars are obtained from the standard
deviation of three average values from nonoverlapping time blocks: 200–
300 ns, 300–400 ns, and 400–500 ns. The survival ratio is the ratio of the
number of hydrogen bonds maintained in the PBP to the total number of
15 in the intact PBP. The histogram in D is based on a subset of data
from the last 300 ns of simulations.
1554 Jiang et al.In Fig. 5 C, the calculation of b-content is broken down
into PBP and APM peptides. The plot clearly shows that
resveratrol acts differently on aggregates than on free
peptides in solution. PBP peptides have ~17% more b-struc-
ture than APM peptides at 315 K in the presence of resver-
atrol, and the difference eventually vanishes when the
temperature is >400 K. In contrast, without resveratrol, b-
structure populations are not dependent on the initial struc-
tures at any temperature. Thus, the effects of resveratrol are
dependent on conformational state: resveratrol inhibits the
b-sheet transition of monomeric peptides while holding
the existing b-structure.
In the initial PBP configuration, 15 backbone hydrogen
bonds were formed that can be regarded as preformed
hydrogen bonds. To trace their survival during the simula-
tion, in each snapshot, a ratio between the number of pre-
formed hydrogen bonds and the total number of hydrogen
bonds was calculated. The evolution of this ratio is plotted
in Fig. S2. The related population of the ratio is shown in
Fig. 5 D. Data were obtained from the last 100 ns simulation
at the lowest temperature. At a ratio of 0, where all pre-
formed hydrogen bonds are lost, the population nearly
doubles in the case without resveratrol compared to the
case with resveratrol. The loss of preformed hydrogen bondsBiophysical Journal 100(6) 1550–1558can happen in the process of dissociation and reassociation
of peptides, as well as during reorientation from parallel to
antiparallel b-sheets. On the other hand, the high peak at
a ratio of 0.65 for the system in the presence of resveratrol
indicates that resveratrol stabilizes the preformed hydrogen
bonds. The population analysis clarifies our aforementioned
speculation about the higher b-content found in PBPs, that
is, that resveratrol molecules protect the existing b-sheet
oligomers against reorganization.Destabilization of double-layered b-sheet
aggregates by resveratrol
The distributions of aggregate patterns in the presence of
resveratrol are clearly different from those in the absence
of resveratrol (see Fig. 3, gray bars). Compared with
peptides without inhibitors, it is clear that those with resver-
atrol have a greatly increased population of monomers such
as species 6, 5, and 4, as well as 6*, 5*, and 4*. This result
agrees well with our previous observation suggesting the
induction of a higher population of monomers by resveratrol
molecules (Fig. 5 A). On the other hand, the population of
configurations with double-b-sheet oligomers is clearly
reduced (see also Fig. S6). The double-sheet aggregates
are shown in Fig. 4, G–I, and Fig. S3. In the presence of re-
sveratrol, the hydrophobic residues are buried more favor-
ably by the amphiphilic compounds than by side chains of
other strands. The double-sheet aggregates are more disor-
dered than those in the absence of resveratrol. The double
b-sheets do not have the feature of parallel stacking seen
in the inhibitor-free simulations (Fig. 4, A–F).Inhibitory activities of resveratrol caused by
blocking of intersheet side-chain contacts
A b-sheet pentamer is the dominant configuration (>50%)
in the heptameric aggregates in the presence of resveratrol
(Fig. 3). The formation of pentamers is via elongation of
the PBP tetramer by adding one APM peptide. Because of
the abundance of this kind of aggregate, we focused on
studying the binding preference of inhibitors on the pen-
tamer. As a simple model, the b-sheet pentamer can be
viewed as a truncated single-layer protofibril. The spatial
distribution of resveratrol around the pentamer is illustrated
in Fig. 6. The six-residue peptide is short and forms a turn-
like, twisted parallel b-sheet instead of a flat b-sheet. The
centers of mass of resveratrol molecules are marked as
colored dots. Different colors differentiate the six binding
sites that are the largest populated clusters in the rank of
all 12 clustering resveratrol molecules in the aggregate
species of BSO labeled as 5. Structures belong to the six
binding sites cover 90.1% of all structures we examined.
A generous RMSD cutoff of heavy atoms of 1.25 nm was
used to consider only the positions of small molecules
surrounding the pentamer and neglecting their internal
TABLE 1 Percentages and binding energies of resveratrol
at six binding sites of b-sheet pentamers
Binding site Percentage (%)*
Binding energy (kJ/mol)
DEtotal
y DEnp
z DEp
x
1 33.6 51.05 8.7 77.75 8.6 26.75 8.1
2 30.1 36.65 7.2 65.65 8.8 29.15 4.5
3 9.8 21.75 5.6 44.15 7.8 22.45 4.3
4 8.9 35.75 8.2 57.45 9.6 21.75 4.3
5 4.0 34.15 6.4 57.25 8.5 23.25 4.2
6 3.7 18.65 6.4 34.75 8.9 16.15 3.9
Values are represented as the mean5 SD of 100 structures from each class
with resveratrol binding at different binding sites.
*Percentage of binding at each binding site in relation to the total binding
on the b-sheet pentamers. Only those aggregates with a well-formed b-sheet
pentamer were taken into consideration, and the percentage of these aggre-
gates is ~50%, as shown in Fig. 4.
yDEtotal is the sum of DEnp and DEp.
zDEnp is the sum of binding energies induced by van der Waals interactions
between resveratrol and peptides as well as the surface-area term in solva-
tion energy.
xDEp is the sum of binding energies induced by electrostatic interactions
between resveratrol and peptides, as well as the generalized Born term in
solvation energy.
FIGURE 6 Six binding sites of resveratrol molecules on b-sheet hI-
APP22–27 pentamers (left), with the representative structures at each binding
site (right). Oligomers with size 5 in Fig. 4 were chosen and distribution of
small molecules (colored dots) surrounding the b-sheet pentamers (blue)
was drawn by superimposing the peptides in the middle. Roughly six
binding sites are identified and represented by different colors (hot pink,
Site 1; yellow, Site 2; violet, Site 3; green, Site 4; cyan, Site 5; orange,
Site 6; white, all other sites). The corresponding representative structures
are shown on the right. Arrows point to the longitude direction of the fibril.
Binding sites are shown along the direction of fibril growth (A) and perpen-
dicular to the direction of growth (B). For the sake of clarity, sites on the
front and back sides of the structures are not shown, corresponding to sites
5 and 6 in A and sites 3 and 4 in B.
Resveratrol Inhibition Mechanism 1555conformation and overall rotation. The preferences of the
six binding sites are illustrated by the population of bound
resveratrol therein, as well as by binding energies calculated
by the MM-GBSA model (Table 1).
The high binding preference of resveratrol for the two
surfaces of the protofibril (Sites 1 and 2 in Fig. 6) is clear,
as indicated by highest percentages (33.6% and 30.1% in
Table 1) and lowest binding energies (51.0 kJ/mol and
36.6 kJ/mol in Table 1). Note that polar components,
DEp, are even higher than those binding at other sites.
However, the unfavorable polar interaction is compensated
by an extremely favorable nonpolar component DEnp. The
favorable van der Waals interactions benefit from the hydro-
phobicity of both side chains at the sites and the compound.
In contrast, the compound is less likely to bind at the growth
edges (Sites 5 and 6), as shown by the sparser dot clouds
along the longitudinal direction (Fig. 6 B). Percentages are
lowest for these two sites (4.0% and 3.7%), and binding
energies are also higher (34.1 kJ/mol and 18.6 kJ/
mol). Although the energy penalty originating from polarcontacts is not as high as Sites 1 and 2 (23.2 kJ/mol
and 16.1 kJ/mol at Sites 5 and 6 vs. 26.7 kJ/mol and
29.1 kJ/mol at Site 1 and 2), the hydrophilic nature of Sites
5 and 6, where backbone hydrogen-bond donors and accep-
tors are located, impedes the nonpolar contacts and makes
them less preferential binding sites. The binding preference
for Sites 3 and 4 ranks between the aforementioned two
groups of binding sites in terms of percentages, DEtotal,
DEnp, and DEp.
Lateral association of b-sheets is a prerequisite for further
growth of amyloid fibrils, and intersheet side-chain interac-
tions mainly drive and stabilize this kind of association.
However, the extensive binding of resveratrol to the surface
of sheets can efficiently block the intersheet side-chain
interactions. We counted the atomic contacts between side
chains of the primary BSO and the other peptides, and
between side chains of the primary BSO and resveratrol
molecules (Fig. S4). The two quantities have a strong anti-
correlation, which unambiguously indicates that resveratrol
binding reduces the possibility of b-sheet formation in
a double-layer arrangement.
To characterize the details of the atomic interaction
between resveratrol and peptides, contact maps of four types
of peptide-inhibitor interaction were drawn (Fig. 7). Four
types of interaction between resveratrol and side chains or
main chains of BSOs or monomers were considered sepa-
rately. A contact is believed to form when the distance sepa-
rating a pair of heavy atoms between two partners is <5 A˚.
We calculated the inhibitor-peptide contact numbers/frame/
strand: 12.9 for BSO side chains; a similar value, 12.7, for
monomer side chains; 3.7 for BSO backbones; and 6.1 for
monomer backbones. The transition from unstructured
monomers to BSOs limits exposure of the backbones toBiophysical Journal 100(6) 1550–1558
FIGURE 8 Self-assembly of amyloidogenic peptides and suggested
inhibitory mechanism of resveratrol. When monomers attempt to integrate
into a fibril nucleus, aggregates grow in two directions, by lateral associa-
FIGURE 7 Contact maps of heavy atoms on resveratrol (abscissa) and on
the residues of peptides (ordinate). The contact intensities have been
normalized by dividing the individual largest contact occurrence number
(in parentheses next to the color bar). Contacts on residues are divided
into four groups: backbones of BSOs (A), side chains of BSOs (B), back-
bones of monomers (C), and side chains of monomers (D). The atoms of
resveratrol are ordered according to spatial proximity in chemical structure
rather than sequence atomic numbers (see Fig. 1 for the chemical structure).
1556 Jiang et al.inhibitors by reducing the contact numbers by nearly half
(from 6.1 to 3.7). Despite the similar contact numbers on
side chains, when the peptide is in a monomeric state, re-
sveratrol has an overwhelming preference for the aromatic
F23 over the other two hydrophobic residues, I26 and L27
(Fig. 7 D). This preference is attenuated when the peptide
is part of a protofibril. The result is consistent with the
less frequent binding at Site 3, where F23 locates, as shown
in Fig. 6. When inhibitors bind to specific positions on
ordered oligomers, stereospecific features, such as the exis-
tence of hydrophobic grooves on the surface, are recognized
by compounds. However, when inhibitors interact with
unstructured monomers, there is no particular structural
motif on the unfolded peptides. Therefore, physicochemical
properties of the compound and single residue, such as
aromaticity or hydrophobicity, rather than tertiary struc-
tures, determine the interactions. In addition, the middle
region of resveratrol shows the largest contact intensities
with side chains of peptides (Fig. 7, B and D). In contrast,
three hydroxyl groups on the resveratrol make polar
contacts with peptides that are mainly located on the
terminal residues (F23 and L27) and exclusively involved
with backbones (Fig. 7 A). The information derived from
contact maps confirms the previous results of favorable
nonpolar binding energies on Sites 1–4 and less favorable
polar binding energies on Sites 5 and 6 (Table 1). Also,
the differences in binding energy at different sites are
mainly caused by physiochemical properties of the binding
site.tion and longitudinal elongation (path 1). The end product is a multiple-
layer fibril. When peptides are incubated with resveratrol, resveratrol is
capable of blocking the lateral growth, whereas longitudinal elongation
remains nearly intact (path 2). Black and gray are used to distinguish
b-strands belonging to different layers. Dashed arrows represent the nascent
b-strands in oligomers.DISCUSSIONS
The main focus of this study is to elucidate the inhibition
mechanism of an antiaggregation compound, resveratrol.Biophysical Journal 100(6) 1550–1558A short segment of hIAPP22–27 (NFGAIL) was studied as
a model system. To better observe the inhibitory effects of
the compound, simulations of peptides with and without
resveratrol were performed. Our results suggest that the
inhibitory mechanism of resveratrol is to block lateral asso-
ciation that occurs at the very early stage of aggregation.
Such a mechanism does not contradict an inhibitory mech-
anism that comes into play later in the fibril elongation
process, in which inhibitor molecules occupy the surface
grooves on the well-formed fibril edge (31–33).
There are quite a few interesting experimental studies on
the inhibitory mechanism of fibril formation of IAPP and
Ab proteins by resveratrol (7,8,12,34,35). IAPP and Ab
amyloid show a similar secondary structure in the fibrillar
state and share amino acid sequence in the ordered region
(36). When resveratrol is added, the usual fibrillation
pathway is diverted to an off-pathway product consisting
of spherical amorphous oligomers with dominant secondary
structure of random coil. It is important to note that these
spherical structures are not cytotoxic (7,34,35). The link
between cytotoxicity and IAPP fibril formation could be
multifactorial, e.g., involving the incorporation of lipid
upon IAPP fibril formation (12,37), or hydrophobic expo-
sure of the fibrillar intermediates (38).
In our simulations, the presence of resveratrol causes the
redistribution of oligomer species. One of the prominent
features is that the ordered hydrophobic matching patterns
demonstrated in the double-layered oligomer species
(Fig. 5) are greatly diminished. Even though the molecules
we studied are peptide segments, we believe that the mech-
anism identified in this study will apply to the full-length
protein as well. We propose the following putative inhibi-
tory mechanism based on the results of our simulations
(Fig. 8). In the path leading to the native end-product
(path 1), aggregates grow both laterally and longitudinally,
driven by hydrophobic matching by the side chains as
Resveratrol Inhibition Mechanism 1557well as hydrogen bonds on the backbone. When resveratrol
interferes with this path, aggregates can only elongate in the
longitudinal direction (path 2). Based on this study, there is
no hint about whether these single-layer b-sheets can
continue to grow into a single-layer fibril or the fibril inter-
mediate species is just too fragile to grow further. We found
no indication that typical fibrils formed when full-length
hIAPP was incubated with resveratrol in vitro (7,12). The
observations seem consistent with available protofibril
structure models (29,39–44) in which the steric zippering
of side chains is one major factor in stabilization of the fibril
structures. Thus, if resveratrol acts on the full-length hIAPP
with the same mechanism observed here for hIAPP22–27, it
appears that inhibition of lateral growth is active enough
to fully abolish fibril formation.SUPPORTING MATERIAL
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